Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: A potential treatment strategy

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 227-235

  Itamochi, Hiroaki ^a,b   Kigawa, Junzo ^a   Kanamori, Yasunobu ^a   Oishi, Tetsuro ^a   Bartholomuesz, Chandra ^b   Nahta, Rita ^b   Esteva, Francisco J ^b   Sneige, Nour ^b   Terakawa, Naoki ^a   Ueno, Naoto T ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 9; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN BAX; PROTEIN P53; PROTEIN P73; TRASTUZUMAB;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLEAR CELL CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; DISEASE MODEL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STABILITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE THERAPY; WESTERN BLOTTING; WILD TYPE;

ADENOCARCINOMA, CLEAR CELL; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE THERAPY; HUMANS; MICE; MICE, SCID; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; THERMODYNAMICS; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846811285     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0499     Document Type: Article

References (56)

1. Scully RE. World Health Organization classification and nomenclature of ovarian cancer. J Natl Cancer Inst Monogr 1975;42:5-7.
2. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol 1971;37:860-7.
3. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-9.
4. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
5. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-7.
6. Kita T, Kikuchi Y, Kudoh K, et al. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 2000;7:327-31.
7. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
8. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57.
9. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999;18:138-43.
10. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998;22:181-90.
11. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
12. Wang ZR, Liu W, Smith ST, Parrish RS, Young SR. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp Mol Pathol 1999;66:140-8.
13. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859-66.
14. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003;9:5078-84.
15. Moran E, Mathews MB. Multiple functional domains in the adenovirus E1A gene. Cell 1987;48:177-8.
16. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu proto-oncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 1990;87:4499-503.
17. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 1998; 17:2167-75.
18. Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci U S A 1991;88:9077-81.
19. Frisch SM, Dolter KE. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res 1995;55:5551-5.
20. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19:3422-33.
21. Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001;7:1237-45.
22. Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. Oncogene 1991;6:343-5.
23. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992;90:626-30.
24. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
25. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J Biol Chem 2000;275:8027-31.
26. Okada S, Tsuda H, Takarabe T, Yoshikawa H, Taketani Y, Hirohashi S. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn J Cancer Res 2002;93:798-806.
27. Ho ES, Lai CR, Hsieh YT, et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001;80:189-93.
28. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998;12:2434-42.
29. Flinterman M, Guelen L, Ezzati-Nik S, et al. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem 2005;280:5945-59.
30. Bartholomeusz C, Itamochi H, Yuan LX, et al. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 2005;65:8406-13.
31. Fujimura M, Katsumata N, Tsuda H, et al. HER2 is frequently overexpressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 2002; 93:1250-7.
32. Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001;61:4892-900.
33. Deng J, Kloosterbooer F, Xia W, Hung MC. The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Res 2002;62:346-50.
34. Nakajima T, Morita K, Ohi N, et al. Degradation of topoisomerase Ilα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 1996; 271:24842-9.
35. Nakajima T, Kimura M, Kuroda K, et al. Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase Ilα during adenovirus E1A-induced apoptosis. Biochem Biophys Res Commun 1997;239:823-9.
36. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci U S A 1992;89:7742-6.
37. Shao R, Karunagaran D, Zhou BP, et al. Inhibition of nuclear factor-κB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem 1997;272:32739-42.
38. Sanchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 1996;13:1083-92.
39. Shao R, Hu MC, Zhou BP, et al. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition Of IκB kinases and nuclear factor κB activities. J Biol Chem 1999;274:21495-8.
40. Routes JM, Ryan S, Clase A, et al. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J Immunol 2000;165:4522-7.
41. Najafi SM, Li Z, Makino K, Shao R, Hung MC. The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. Biochem Biophys Res Commun 2003;305:1099-104.
42. Chattopadhyay D, Ghosh MK, Mal A, Harter ML. Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J Virol 2001;75:9844-56.
43. Flinterman M, Gaken J, Farzaneh F, Tavassoli M. E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines. Oncogene 2003;22:1965-77.
44. Shihle M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
45. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
46. Righetti SC, Delia Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
47. Kraiss S, Spiess S, Reihsaus E, Montenarh M. Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp Cell Res 1991;192:157-64.
48. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
49. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
50. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
51. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
52. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-4.
53. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents [review]. Int J Oncol 2002;21:1161-74.
54. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer [review]. Int J Oncol 2002;21:461-8.
55. Zeimet AG, Muller-Holzner E, Schuler A, et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 2002;9:1093-100.
56. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001;8:341-8.